Poxel SA is primarily active in the pharmaceutical industry.

The main competitors of Poxel SA in the market include pharmaceutical companies such as Novo Nordisk, Sanofi, and Eli Lilly.

Poxel SA is a pharmaceutical company specializing in the development of innovative treatments for metabolic diseases. Founded in 2009, the company is headquartered in Lyon, France. Poxel focuses on developing drugs that address unmet medical needs in areas such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). The company's research and development efforts are supported by a robust pipeline and collaborations with renowned academic institutions and strategic partners. Poxel's mission is to improve the lives of patients worldwide by providing effective therapeutic solutions. With its commitment to scientific excellence and patient-centric approach, Poxel is at the forefront of advancing treatments for metabolic diseases.

Poxel SA, a renowned French biopharmaceutical company, has accomplished significant milestones in its journey. Notably, Poxel SA successfully completed the Phase 3 trials for its lead product, Imeglimin, a potential groundbreaking treatment for type 2 diabetes. Additionally, the company received positive feedback from regulatory authorities, advancing its development plans globally. Furthermore, Poxel SA secured strategic partnerships and collaborations with esteemed organizations to enhance its research and development efforts. These achievements demonstrate Poxel SA's dedication to revolutionizing healthcare through innovative therapies.

Poxel SA is primarily present in various countries and regions worldwide. The company has a strong presence in Europe, with a focus on France, Germany, and Italy. Additionally, Poxel SA operates in North America, particularly in the United States. The company also has a presence in Asia, with key markets including Japan and South Korea. With its global outreach, Poxel SA is constantly expanding its geographical footprint to reach more markets and serve a broader customer base.

Poxel SA represents a strong set of values and corporate philosophy. The company is committed to driving innovation and advancing scientific research in the field of metabolic disorders. Poxel SA prioritizes integrity, professionalism, and collaboration, which are embodied in its dedicated team and partnerships. With a focus on patient-centricity, Poxel SA strives to develop effective treatments for serious conditions like type 2 diabetes and non-alcoholic steatohepatitis. By leveraging its expertise and leveraging cutting-edge technologies, Poxel SA aims to make a positive impact on patients' lives worldwide.

Analysts currently set an average price target of 3,57 EUR for the Poxel stock (median: 3,57 EUR), implying +1 663,0 % versus the latest price. The consensus is based on 9 analyst ratings.

Poxel Analyytikkojen kursstavoitteet 2026

9 analysts currently rate the Poxel stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Poxel to generate revenue of 39,27 M EUR and earnings per share of −1,82 EUR.

Poxel Analyytikkojen kursstavoitteet 2026

The Poxel share (POXEL.PA) is listed on 6 stock exchanges, including: Frankfurt (7PO.F), München (7PO.MU), London (0RA2.L), Paris (POXEL.PA).

Poxel SA is a French biopharmaceutical company focused on developing and marketing groundbreaking therapeutics for the treatment of metabolic diseases. The company collaborates closely with prominent academic institutions and research facilities worldwide to develop innovative solutions aimed at improving patients' quality of life. The company offers a wide range of products, including Imeglimin, a novel molecule that improves mitochondrial function and increases insulin sensitivity in the body. Imeglimin aims to treat type 2 diabetes and other metabolic diseases by directly acting on the insulin sensitivity of cells. Another important product of Poxel SA is PXL770, a small molecule that stimulates the AMPK signaling pathway. This improves insulin sensitivity and can help combat obesity and other metabolic diseases. The company has also entered into a collaboration with Roivant Sciences to develop a treatment program for non-alcoholic steatohepatitis (NASH). This involves testing a compound called PXL065, which is intended to act in the liver and could help reduce inflammation and fibrosis. To finance the development and marketing of these products, Poxel SA utilizes a unique business model that is based on collaboration with strategic partners, as well as clinical studies and licenses. The company works closely with leading players in the pharmaceutical industry to develop and market its products. Through licensing agreements and the sale of research and development to partner companies, the company can bring its products to market and simultaneously finance its research and development activities. Furthermore, Poxel SA employs innovative business models to accelerate the development and marketing of its products. The company is heavily involved in the research and development efforts of its partners, utilizing state-of-the-art scientific methods and technologies. The company also collaborates closely with academic institutions and research facilities to develop new therapies and technologies targeting metabolic diseases. Overall, Poxel SA is an innovative company focused on the development and marketing of metabolic therapies. Through collaboration with other pharmaceutical companies and academic institutions, the company is able to bring its products to market, finance its research and development, and improve the quality of life for patients worldwide.

odotettu liikevaihto Poxel on 39,27 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Poxel on −93,51 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Poxel:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,11. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Poxel-osakkeen arvostusta.

Poxel:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,26. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Poxel-osakkeen arvostuskennuslukuna.

Poxel:n Eulpool-laatuscore on 2/10.

Poxel:n ISIN on FR0012432516. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Poxel:n WKN on A14M04. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Poxel:n ticker on POXEL.PA. Tämä pörssinoteeraus käytetään Poxel-osakkeiden kauppaan pörssissä.

Poxel maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Poxel kuuluu sektoriin 'Terveydenhuolto'.

Poxel:n osingot jaetaan valuutassa EUR.